| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.018 | 0.8 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.019 | 0.8 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | 0.02 | 0.7 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.025 | 0.7 |
| mRNA | Vorinostat | gCSI | pan-cancer | AAC | -0.026 | 0.6 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | -0.03 | 0.6 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | -0.049 | 0.4 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | 0.053 | 0.4 |
| mRNA | bid1870 | gCSI | pan-cancer | AAC | 0.057 | 0.4 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | -0.057 | 0.3 |